West Pharmaceutical Services (WST) Projected to Announce Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) is anticipated to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $2.20 per share and revenue of $827.12 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

West Pharmaceutical Services Stock Up 0.6%

WST stock opened at $394.68 on Tuesday. West Pharmaceutical Services has a one year low of $223.83 and a one year high of $397.15. The stock has a market capitalization of $27.78 billion, a PE ratio of 50.53, a price-to-earnings-growth ratio of 2.75 and a beta of 1.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The company has a fifty day moving average of $363.12 and a 200-day moving average of $310.55.

West Pharmaceutical Services Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th will be paid a dividend of $0.26 per share. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Tuesday, November 10th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is currently 11.27%.

Insider Transactions at West Pharmaceutical Services

In related news, VP Annette Favorite sold 2,524 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $365.00, for a total value of $921,260.00. Following the sale, the vice president owned 21,818 shares of the company’s stock, valued at approximately $7,963,570. This represents a 10.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 15,659 shares of company stock valued at $5,443,749. 0.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have weighed in on WST. Wall Street Zen lowered shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays lifted their price target on shares of West Pharmaceutical Services from $400.00 to $440.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Zacks Research lowered West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. UBS Group upped their price target on West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Finally, KeyCorp upped their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Twelve equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and an average target price of $391.17.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.